Background. There is increasing evidence regarding the involvement of inflammation processes in patients with intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Aim. To evaluate the circulating concentrations of MMP-3 and TIMP-2 in patients with IPMNs and in those with ductal adenocarcinomas. Patients. Sixty patients (32 males, 28 females, mean age 69.3±11.3 years) were enrolled: 31 (51.7%) had IPMNs and 29 (48.3%) had histologically confirmed pancreatic adenocarcinomas. Thirty blood donors were also studied as controls. Methods. The serum concentrations of MMP-3 and TIMP-2 were determined in all study subjects using commercially available kits. Results. Serum concentrations of MMP-3 were significantly higher both in patients with pancreatic ductal adenocarcinomas and in those with IPMNs as compared to the healthy subjects whereas serum levels of TIMP-2 were significantly lower both in IPMN patients and in patients with pancreatic adenocarcinomas than in those of the healthy subjects. No significant differences in the serum levels of both MMP-3 and TIMP-2 were found between patients with IPMNs and those with pancreatic adenocarcinomas, and, in the patients with IPMN, they were not related to the type of tumor. Conclusions. IPMNs have a pattern of extracellular matrix factors and their inhibitors are similar to those of ductal adenocarcinoma; MMP-3 and TIMP-2 cannot be utilized to routinely differentiate IPMNs from ductal adenocarcinomas.
I ntraductal papillary mucinous neoplasms (IPMNs) of the pancreas are a group of slow-growing tumors as compared to pancreatic ductal adenocarcinomas *1+. Among the causes of the aggressive behavior of ductal exocrine pancreatic tumors, the extracellular matrix is essential for cancer invasion and metastatization, and matrix metalloproteinases (MMP)s have been considered useful markers of these phenomena on tissue specimens *2-4+. On the other hand, it has been shown that immunoreactivity for the tissue inhibitor of metalloproteinases (TIMPs) in pancreatic and ampullary cancers with lymph node metastases was significantly lower than in patients without lymph node metastases *3+. In human pancreatic cancer, MMP-2, MMP-9, TIMP-1 and TIMP-2 may be involved in processes leading to the strong desmoplastic reaction observed in these tumors; both stromal and tumor cells appear to be the source of MMPs and TIMPs in human pancreatic cancer *5+.
It has been reported that circulating MMP-9 and TIMP-1 were not useful serum markers for detecting pancreatic ductal adenocarcinoma as compared to CA19-9 *6+. In addition, MMPs and TIMPs have been studied in pancreatic ductal adenocarcinoma and, regarding their presence, knowledge in patients with pancreatic IPMNs is lacking. Thus, the aims of the present study were to evaluate the circulating concentrations of MMP-3 and TIMP-2 in malignant diseases of the pancreas, such as IPMNs and pancreatic adenocarcinomas, and to also evaluate the concentrations of these molecules in comparison to CA 19-9.
Patients
Consecutive patients, eighteen years of age or older, who were admitted to the Unit for the Study of Pancreatic Diseases of Sant'Orsola-Malpighi Hospital of Bologna (Italy) for exocrine pancreatic neoplasms between October 2007 and December 2009 were eligible for the study.
A total of 60 patients (32 males, 28 females, mean age 69.3±11.3 years) were enrolled: 31 (51.7%) had IPMNs diagnosed by imaging (by using the accepted internationalcriteria *7+) or at surgery and 29 (48.3%) had histologically-confirmed pancreatic adenocarcinomas. The body mass index (BMI) was stratified according to the WHO classification *8+, and pancreatic insufficiency was defined as a fecal elastase-1 concentration of less than 200 μg/g *9+. At the time of the study, none of the patients had had any treatment for their disease. Of the 31 patients with IPMNs, 16 (51.6%) had branch type IPMNs and the remaining 15 (48.4%) had main duct type IPMNs.
As previously reported *9+ (Table 1) , the two groups of patients Finally, 30 blood donors were also studied as healthy controls (17 males, 13 females; mean age 59.7±8.1; P=0.825 and P<0.001 vs. the sex and the age of patients, respectively).
Methods
Blood specimens were obtained in the morning in a fasting state from each subject enrolled. Laboratory personnel were unaware of the clinical diagnoses or the details of the patients' clinical histories. The serum specimens were stored at -20°C until analysis.
Concentrations of MMP-3 and TIMP-2 were determined using enzyme-linked immunosorbent assays (ELISA) (R&D System, Minneapolis, MN, USA). This analysis employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for this molecule was pre-coated onto a microplate. After dilution, standards and samples were pipetted into the wells to allow the link of specific molecules to immobilize the antibody. After washing away any unbound substances, an enzyme-linked monoclonal antibody specific for MMP-3 and TIMP-2 was added to the wells. After removing any unbound antibody-enzyme reagent, a substrate solution was added to the wells and colour developed in proportion to the amount of our specific molecules. The reaction was stopped with 50 mL HCl and the intensity of the colour was measured at 450 nm. The dilution factor was recorded in order to calculate the concentration of MMP-3 and TIMP-2 in the samples.
The maximum intra-and inter-assay CVs were 6.1 and 7.8 for MMP-3 and 3.6 and 6.6 for TIMP-2. The detection limits were 0.009 ng/mL for MMP-3 and 0.011 ng/mL for TIMP-2.
Ethics
The study was approved by the Clinical Committee of the Department of Internal Medicine of Sant'Orsola Hospital of Bologna (Italy) and was carried out in accordance with the Helsinki Declaration of the World Medical Association. All subjects gave written informed consent to participate in the study.
Statistical analysis
Means, standard deviations and frequencies were used as descriptive statistics. Data were analyzed by means of the Kruskal-Wallis test, Fisher's exact test, linear-by-linear association chisquare and Pearson chi-square.
The SPSS (SPSS Inc., Chicago, IL, Ver. 13.0) statistical package was used to analyze the data. Two-tailed P values of less than 0.05 were considered statistically significant.
Results
The mean ± SD values of MMP-3 and TIMP-2 in the three groups of subjects studied are reported in Table 2 . Serum concentrations of MMP-3 were significantly higher both in patients with pancreatic ductal adenocarcinomas and in those with IPMNs as compared to the healthy subjects whereas serum levels of TIMP-2 were sig- 
Discussions
Patients with pancreatic adenocarcinomas have a poor outcome; on the other hand, IPMNs of the pancreas are slow-growing neoplasms which can be cured surgically in most patients *11+. The differences between the two neoplasms are also confirmed by the clinical data of our study; in fact, patients with ductal adenocarcinoma had a frequency of pain, diabetes, jaundice and metastases significantly higher than those with IPMNs as well as having a significantly lower BMI. At present, there are no data regarding the circulating levels of MMPs and TIMPs released by pancreatic IP-MNs. Thus, we undertook the present study in order to evaluate MMP-3 and TIMP-2 in patients with malignant chronic diseases of the pancreas, such as pancreatic adenocarcinomas and IPMNs, for a better understanding of the circulating concentrations of the factors which evaluate the extracellular matrix, such as MMP-3 and its inhibitor (TIMP-2), and to assess their diagnostic role.
For the first time, serum levels of MMP-3 and TIMP-2 were evaluated in patients with IPMNs as compared to those with pancreatic adenocarcinomas. We found that serum concentrations of MMP-3 and CA 19-9 were significantly higher both in patients with pancreatic ductal adenocarcinomas and in those with IPMNs than in healthy subjects. These data agree with those previously reported *12+ and indicate that MMPs in patients with IPMNs may also be relevant in determining carcinoma invasion. Similarly, TIMP-2 serum concentrations were significantly lower in IPMN patients and in patients with pancreatic ductal adenocarcinomas as compared to healthy subjects, indicating that, in patients with IPMNs, there is also an aggressive phenotype because thye overexpression of MMP-3 is associated with a diminished expression of TIMP-2.
Within the group of patients, no significant differences were observed for MMP-3 and TIMP-2 between patients with metasta-ses, pain, jaundice, diabetes as compared to those without, and those with pancreatic exocrine insufficiency and those with pancreatic exocrine sufficiency. On the basis of these results, MMP-3 and TIMP-2 do not seem to have the characteristics of a diagnostic marker for pancreatic carcinoma. This finding is also true in patients with IPMNs because patients with branch type IPMNs had serum values of MMP-3 and TIMP-2 similar to those having main duct IPMNs.
In conclusion, IPMNs have a pattern of extracellular matrix factors, and their inhibitors are similar to those of ductal adenocarcinoma. However, these proteins cannot be utilized to routinely differentiate pancreatic IPMNs from pancreatic ductal adenocarcinomas.
